危重症患者接受连续性肾脏替代治疗时美罗培南的人群药代动力学荟萃分析与给药建议
该研究利用9项已发表研究、78例成人CRRT患者的501个美罗培南浓度数据建立人群PK模型,并模拟不同输注策略下40%和100% fT>MIC的达标概率及谷浓度>45 mg/L的毒性风险。结果显示,非创伤CRRT患者采用1 g每6 h输注30 min、1 g每8 h输注3 h或2–4 g每24 h输注24 h可达标且毒性风险低;创伤是美罗培南内源性清除的显著修饰因素,创伤CRRT患者(MIC≤0.5 mg/L)适合3–4 g每24 h持续输注。CRRT剂量(25–50 mL/kg/h)对达标概率的影响无临床意义。作者据此提出非创伤与创伤CRRT患者的不同给药方案。
要点
- 非创伤CRRT患者:美罗培南1 g每6 h输注30 min、1 g每8 h输注3 h或2–4 g每24 h输注24 h可达PK/PD目标且毒性风险低。
- 创伤是美罗培南内源性清除的显著修饰因素;创伤CRRT患者(MIC≤0.5 mg/L)适合3–4 g每24 h持续输注。
- PK/PD目标为40%和100% fT>MIC;毒性风险定义为谷浓度>45 mg/L。
- CRRT剂量25–50 mL/kg/h对达标概率的影响无临床意义。
- 模型基于9项研究78例成人CRRT患者的501个浓度数据,采用二室线性消除模型。
适用人群与场景
- 成人危重症患者,正在接受连续性肾脏替代治疗(CRRT),数据来自9项已发表研究、共78例。
诊断标准与关键阈值
- PK/PD目标:游离药物血浆浓度高于MIC的时间占给药间隔的40%和100%(40%和100% fT>MIC)。
- 毒性风险阈值:谷浓度>45 mg/L。
处置流程与药物剂量
- 非创伤CRRT患者:美罗培南1 g每6 h输注30 min,或1 g每8 h输注3 h,或2–4 g每24 h输注24 h,可达 adequate PK/PD目标且毒性风险低。
- 创伤CRRT患者(MIC≤0.5 mg/L):美罗培南3–4 g每24 h持续输注(24 h)适合。
- CRRT剂量25–50 mL/kg/h对达标概率的影响无临床意义。
研究设计与关键结果
- 研究类型:人群药代动力学/药效学荟萃分析;数据来源:9项已发表研究、78例成人CRRT患者、501个美罗培南浓度测量值。
- 模型:二室模型、线性消除;创伤被确定为美罗培南内源性清除的显著修饰因素。
- 模拟结果:非创伤CRRT患者采用1 g每6 h输注30 min、1 g每8 h输注3 h或2–4 g每24 h输注24 h可达 adequate PK/PD目标且毒性风险低。
- 创伤CRRT患者(MIC≤0.5 mg/L):3–4 g每24 h持续输注适合。
- CRRT剂量25–50 mL/kg/h对达标概率的影响无临床意义。
证据类型、等级与局限
- 证据类型:基于文献数据的人群药代动力学/药效学荟萃分析(汇总9项已发表研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者提出非创伤与创伤CRRT患者可采用不同的美罗培南给药方案:非创伤者1 g每6 h输注30 min、1 g每8 h输注3 h或2–4 g每24 h输注24 h;创伤者(MIC≤0.5 mg/L)3–4 g每24 h持续输注。
- CRRT剂量在25–50 mL/kg/h范围内时,无需因CRRT剂量调整美罗培南给药方案以追求达标概率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
The optimal dosing regimen for meropenem in critically ill patients undergoing continuous renal replacement therapy (CRRT) remains undefined due to small studied sample sizes and uninformative pharmacokinetic (PK)/pharmacodynamic (PD) analyses in reported studies. The present study aimed to perform a population PK/PD meta-analysis of meropenem using available literature data to suggest the optimal treatment regimen. A total of 501 meropenem concentration measurements from 78 adult CRRT patients pooled from nine published studies were used to develop the population PK model for meropenem. PK/PD target (40% and 100% of the time with the unbound drug plasma concentration above the MIC) marker-based efficacy and risk of toxicity (trough concentrations of >45 mg/L) for short-term (30 min), prolonged (3 h), and continuous (24 h) infusion dosing strategies for meropenem were investigated. The impact of CRRT dose and identified covariates on the PD probability of target attainment (PTA) and predicted toxicity was also examined. Meropenem concentration data were adequately described by a two-compartment model with linear elimination. Trauma was identified as a pronounced modifier for endogenous clearance of meropenem. Simulations demonstrated that adequate PK/PD targets and low risk of toxicity could be achieved in non-trauma CRRT patients receiving meropenem regimens of 1 g every 6 h infused over 30 min, 1 g every 8 h infused over 3 h, and 2 to 4 g every 24 h infused over 24 h. The impact of CRRT dose (25 to 50 mL/kg/h) on PTA was clinically irrelevant, and continuous infusion of 3 to 4 g every 24 h was suitable for trauma CRRT patients (MICs of ≤0.5 mg/L). A population PK model was developed for meropenem in CRRT patients, and different dosing regimens were proposed for non-trauma and trauma CRRT patients.
参考来源
- Peng Y, Cheng Z, Xie F, et al. Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy. Antimicrob Agents Chemother. 2022. PMID: 36005753. doi:10.1128/aac.00822-22
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。